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From the Editor’s Desk
The Department of Pathology and Microbiology
is committed to providing high quality diagnostic
services for physicians and hospitals nationwide.
One of the functions of the Department is to
update physicians throughout Pakistan about
the advancement in laboratory sciences and the
services available at the Clinical Laboratory
for disease diagnosis, through our Laboratory
Updates and this newsletter, LABRAD.
The current issue of the LABRAD focuses on
measurements related to bone disorders in an
attempt to give readers a better understanding
of the diagnostic modalities available at Aga
Khan University Hospital Clinical Laboratories.
Bone disease is a vast topic which interests a
diverse group of medical professionals such
as: internists, rheumatologist, orthopaedics,
endocrinologist, gynaecologists, paediatricians
and geriatrics, researchers in anatomy,
physiology, nutrition, biochemistry, pathology
and imaging. Diversity of interest is due
to a combination of problems ranging
from
malnutrition
in
the
developing
world
to
the
aging
populations
of the developed world.
Several factors may influence the choice of a
method for the measurement of bone disease.
A major limiting factor in establishment of
a service for measurement of bone diseases

is the local availability of equipment and
methodology, and also the availability of the
required expertise and knowledge for the
interpretation of results. Choice of the tests also
depends on the type of information required
from investigating a patient suspected of
having a bone disease and achieving this aim as
economically as possible in less time and money.
This issue concentrates on common bone
related clinical problems; focusing on practical
usefulness of various tests available for diagnosis
and management of bone diseases in the field.
Biochemical bone profiles have been developed
in the section of chemical pathology to help the
physician in evaluating a patient suspected of
having metabolic bone diseases. Combination of
information on different microbiological tools
for facilitating management of bone infection
along with diagnostic tools available for
identifying disorder like ankylosing spondylitis
are also presented. On the whole this is a
broad sweep of information collected through
individual disciplines and we hope it will
improve as our newsletter evolves through a
cyclic process of learning and sharing with
our readers.
We hope this edition would help increase your
knowledge banks and would answer many of
your questions. We are hopeful for making this
issue a useful document for future reference
in the bone disease area. Happy reading!

3

September 2011, Vol. 37, Issue 2

Biochemical Bone Profiles Available at Clinical
Laboratory of Aga Khan University Hospital
Dr Farhan Javed Dar
Chemical Pathology

The utility of bone profiles in screening and diagnosis
of bone diseases have a profound effect upon bone
health. Choosing any screening profile helps to rule out
metabolic bone diseases such as vitamin D deficiency,
osteoporosis. Panels are made to make clinical
interpretation easy for physicians and economical
for patients.
Following profiles are available at Clinical Laboratory
AKU for diagnosis and monitoring of bone disorders.
Only 5 ml of blood is sufficient for any one of the
panel as shown in the table.

when we are young will help prevent problems in
the future.
Commonly encountered bone diseases include those
related to vitamin D deficiency (rickets in children and
osteomalacia in adults), osteoporosis, osteogenesis,
imperfecta and Paget’s disease of bone. Bone disease
can lead to fragile and brittle bones, which break easily.
AKUH clinical laboratory is now providing Bone
Health Panel, (please refer to the table below) which
helps in assessment of bone health. This profile is

BIOCHEMICAL BONE PROFILE
Bone Health Panel
Calcium
Phosphorus
Albumin
Magnesium
Alkaline phosphatase (ALP)
Creatinine
Intact parathyroid hormone (iPTH)
25-hydroxy vitamin D (25-OHD)
Bone Health Panel
Bone health is important throughout the lifetime of
an individual. Bones protect our internal organs from
damage, they are the factory of our blood cells and
are the storehouse for minerals and nutrients (such as
calcium and phosphorus) needed in the body. With all
of these critical functions for our health, understanding
how to maintain and build healthy bones is an important
part of investigating for a healthy future.
It is especially important to build strong and healthy
bones during childhood and teen years to avoid
osteoporosis and other bone problems later in life.
After the mid-30s, bone loss slowly begins to occur.
Women lose bone quickly after menopause.
Importantly, healthy habits can help to limit the
bone loss that occurs. Taking care of our bones
4

Osteoporosis Panel
Calcium
Phosphorus
Albumin
Alkaline phosphatase (ALP)
25-hydroxy vitamin D (25-OHD)
Intact parathyroid hormone (iPTH)
N-telopeptide of type I collagen (NTx)

intended to screen, investigate and monitor patients
with disorder of calcium and bone metabolism. It
provides answer to the potential clinical questions
that a physician seeks when investigating for
metabolic bone diseases for example; does my patient
have hypocalcaemia or hypercalcaemia? If there is
hypercalcaemia, is it due to hyperparathyroidism or
a parathyroid hormone independent cause? If it is
hypocalcaemia, is it due to parathyroid failure, vitamin
D deficiency or renal failure? Does my patient have
hypomagnessemia? If the patient has aches and pains
or unexpected fracture then is it due to metabolic
bone disease?
Osteoporosis Panel
Osteoporosis is a systemic skeletal disorder
characterised by low bone mass and micro architecture
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deterioration of bone tissue with a consequent increase
in bone fragility and susceptibility to fracture.
According to WHO by 2025, almost 3 million of
the global population will suffer from osteoporosis
which will be expected to rise to 6.3 million by 2050.
About 75 percent of this 6.3 million hip fractures
will occur in the developing countries, mainly due
to projected large increase of aged population.
Osteoporosis is a costly disease due to its chronic

nature, severity of its complications and means
required to treat it. Osteoporosis is diagnosed late as
patient remains asymptomatic until fracture occurs.
AKUH Clinical Laboratory is providing Osteoporosis
Panel, mentioned in the above table, which helps in
assessment of osteoporosis.
It is to be noted that diagnosis should be made in
correlation with clinical picture and Dual-energy
X-ray absorptionetry (DXA) results.

Ionized Calcium Determination in Clinical
Labortory
Dr Lena Jafri
Chemical Pathology

Plasma calcium exists in three forms ionized (iCa)
(45 to 50 per cent), protein bound (40 per cent) and
calcium complexed with anions (10-15 per cent).
Although all the forms are in equilibrium with
each other, only the plasma iCa has been reported
to be active at cellular level. This parameter has
also been called ‘free’ or ‘ionic’ calcium. It is
considered the best indicator of calcium status
because it is biologically active and tightly
regulated by parathyroid hormone (PTH) and
1, 25 dihydroxy vitamin D. Total calcium level
does not give an indication of what is available
at the cellular level. Only disturbances in iCa
are physiologically relevant.

Analysis of iCa is technically demanding. The sound
analytical performance of today’s iCa analyzers using
ion selective electrode (ISE) technology have made
measurements accurate and precise. iCa recently
introduced in Aga Khan University Clinical Laboratory
after thorough research and understanding of Clinical
Laboratory Standard Institute Guidelines (CLSI) for
sample handling, storage and transportation. Table
1 shows the precautions to be taken prior to blood
sampling for iCa determination and collection.

Precollection Variables and
Recommendations

Collection Techniques

The clinical usefulness of measuring iCa rather
than total calcium is more in disorders with plasma
protein abnormalities like liver failure, protein losing

Have the patient rest for 5-10 min before
collecting blood

If a series of tubes must be collected, fill gel tube
for iCa first

Ensure that the patient has not eaten for at
least 4 hours

Do not leave the tourniquet on for more than 3 		
minutes

Collect specimens under consistent conditions
ideally the patient should be seated

Do not allow the patient to exercise the forearm
or make a fist

Table 1. Recommendations for specimen collection of iCa as per CLSI guidelines

Fill gel tubes completely
Handle specimen anaerobically (do not open the 		
tube until analysis)
5
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nephropathy, burns, cardiac failure or malnutrition.
iCa determination is more useful in those undergoing
major surgery who have received citrated blood/
platelets, heparin, or intravenous calcium.
It should be the test of choice when neonatal
hypocalcemia is suspected, especially if bicarbonate
is given to neonates with hypocalcemia.
Rapid measurement of iCa in intensive care units is
helpful in cases with sepsis and acid base disturbances.
It has been documented that the use of total calcium
is unreliable in cases where there is a change in the
protein-calcium binding characteristics as in patients
with hypergammaglobulinemia or a decrease/increase

in pH. An increase in blood pH is associated with a
decrease in iCa a decreased blood pH is associated
with an increased iCa.
Ionized calcium is also useful in cardiopulmonary
bypass and during hemodialysis where maintenance
of good cardiac function is essential. During
dialysis monitoring a slight positive calcium
balance is important for maintaining good cardiac
contractility. Ionized calcium is the best means to
monitor this.
Literature shows that iCa rather than total
calcium is more useful in malignancies, hypo/
hyperparathyroidism and pancreatitis.

Parathyroid Hormone Disorders and Issues
of Testing
Dr Syed Talha Naeem
Chemical Pathology

Parathyroid hormone (PTH) is secreted by the
parathyroid glands and regulates serum calcium (Ca)
through its effects on the bone, kidney and intestine.
PTH secretion is stimulated by decrease in serum Ca
and magnesium and an increase in serum phosphate,
which in turn raises serum ionized Ca levels through
direct action on bone and the kidneys. Long-term
regulation of total body Ca by PTH occurs through its
stimulation of vitamin D metabolism.
PTH can be measured in the blood in several
different forms: intact PTH; N-terminal PTH; midmolecule PTH, and C-terminal PTH. An intact
PTH (iPTH) provides a better index of parathyroid
function and is the test available in AKUH clinical
laboratory for clinical use.
PTH is secreted in episodic or pulsatile fashion
with an overall circadian rhythm characterised by
a nocturnal rise. Measurement of iPTH on more
than one occasion should minimise the effect of
episodic secretion and circadian rhythm. Because
of the nocturnal rise in iPTH levels, samples should
be collected in the morning, preferably after an
overnight fast.
Determination of iPTH is useful in the differential
diagnosis of disorders of bone and mineral
6

metabolism, including hypocalcaemia and
hypercalcaemia, renal failure and secondary
hyperparathyroidism; when PTH increases long
before Ca becomes abnormally low.
PTH is elevated in the majority of patients with
primary hyperparathyroidism. It is below normal
or in the lower half of the reference interval in
most patients with nonparathyroid hypercalcemia
including hypercalcemia-associated malignancy.
In cases with hypercalcemia, PTH estimation
should be performed before initiating any therapy
to reduce serum Ca; as PTH secretion may be
stimulated by declining but still elevated levels
of serum Ca. This can complicate the differential
diagnosis of hypercalcaemia. In the majority
of patients with hypercalcaemia associated
with malignancy, iPTH is suppressed to levels
below normal or at the lower end of the normal
reference interval. Elevated levels of iPTH in
patients with hypercalcemia and malignancy
suggest coexisting hyperparathyroidism and
malignancy, because ectopic PTH production
appears to be extremely rare.
In secondary hyperparathyroidism, iPTH is increased
before total or free calcium becomes abnormally
low, a consequence of homeostatic mechanisms
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for maintenance of serum Ca. Consequently,
PTH is more sensitive than Ca for identifying
secondary hyperparathyroidism. Subnormal or
normal PTH is observed in the majority of patients
with hypoparathyroidism; such concentrations are
inappropriately low for patients with hypocalcemia.
In patients with end-stage renal disease, measurement
of iPTH is helpful in assessing parathyroid function,
in estimating bone turnover, and in improving
management. Patients with high turnover bone disease
because of secondary hyperparathyroidism (advanced
osteitis fibrosa) have the highest concentrations of
PTH, whereas patients with low-turnover, adynamic
bone disease, including osteomalacia, have the lowest
concentrations. Intermediate levels are found in
patients with low-turnover adynamic (aplastic) disease
and early osteitis fibrosa. Considerable overlap in
iPTH levels is apparent between the various forms of
renal osteodystrophy.
iPTH is also useful intraoperatively, for assessing the
completeness of parathyroidectomy and facilitating
minimally invasive parathyroid surgery, thereby
improving cost-effectiveness and cosmetic outcomes.
PTH levels may be altered in some patients
with hyperthyroidism and hypothyroidism

and may increase after treatment with lithium
carbonate. PTH concentrations are inversely
correlated with T3 levels in hyperthyroid
patients, increase in patients who become
hypothyroid after radioactive iodine treatment,
and decrease with replacement therapy; changes
apparently mediated by serum Ca. Chronic
lithium carbonate therapy has been reported to
increase parathyroid gland size and circulating
intact PTH. Drugs that may increase PTH levels
include phosphates, anticonvulsants, steroids,
isoniazid, lithium, and rifampicin.
Because of the physiological relationship
between circulating Ca and PTH, it is always
important to interpret PTH results in the light
of total or ionized Ca levels. Indices of renal
function, measurements of albumin, as an
adjunct to measurement of total calcium levels
and determinations of phosphorus, chloride,
and magnesium levels may also aid in the
interpretation of PTH and Ca results. It should
also be remembered that hypercalcemia and
hypocalcemia may be secondary to disordered
vitamin D metabolism. For diagnostic purposes
PTH results should always be used in combination
with the clinical examination, patient medical
history, and other findings.

Tubular maximum reabsorption rate of phosphate
to glomerular filtration rate (TmP/GFR)
Dr Noreen Sherazi
Chemical Pathology

Phosphate filters entirely through the glomeruli
but is then largely reabsorbed in the proximal
part of the proximal renal tubule. Several factors
influence the tubular reabsorption of phosphate
(Table 1) by acting on the sodium/phosphate
co transporters.
Tubular reabsorption of phosphate depends on
plasma phosphate and glomerular filtration rate and
is not a satisfactory indicator of tubular phosphate
handling. This has led to increasing use of ‘tubular
maximum for phosphate corrected for GFR (TmP/
GFR)’, a factor independent of plasma phosphate
and renal functions for assessment of renal phosphate
handling. TmP/GFR (Normal 2.8-4.4 mg/dL) is an

index of renal threshold for phosphate which can
be determined directly by the formula TmP/GFR
= Plasma phosphate - (urine phosphate x serum
creatinine)/urine creatinine.
Assessing renal reabsorption of phosphorus is
needed in a variety of pathological conditions
associated with hypophosphatemia including
hypophosphatemic
rickets,
tumour-induced
osteomalacia and tumoral calcinosis. It is also used
in adjusting phosphate replacement therapy in
severe deficiency states; like conditions that cause
phosphate redistribution (e.g. glucose infusion,
respiratory alkalosis), so if hypophosphataemia
persists, a low (fasting) TmP/GFR indicates the
7
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Factors that decrease renal phosphate absorption

Factors that increase renal phosphate absorption

Phosphate-free diet

High dietary phosphate intake

Respiratory acidosis, metabolic alkalosis

Respiratory alkalosis, metabolic acidosis

PTH, PTHrP, EGF, glucocorticoids, catecholamines,
calcitonin, 1,25(OH)2 D3

GH, IGF1, thyroid hormones (T3), insulin

Diuretics
Phosphatonins
Table 1. Factors affecting tubular reabsorption of phosphate

need for phosphate replacement. In the treatment
of severe phosphate deficiency, TmP/GFR can be
used as an indicator of intracellular repletion.
The measurement of TmP/GFR along with other
parameters is required for diagnosis of X-linked
hypophosphataemic
rickets
and
hereditary
hypophosphataemic rickets with hypercalciuria.
Measurement of TmP/GFR is central to the diagnosis

of oncogenic osteomalacia in addition to other
parameters
We, at AKUH clinical laboratory, are starting this
test which will required at least 6-8 hours fasting
serum sample for phosphate and creatinine and
simultaneously taken spot urine sample for phosphate
and creatinine. TmP/GFR will then be calculated
from above mentioned parameters.

LABRAD Quiz
Dr Hafsa Majid
Chemical Pathology

Question #1

1.3: How would this be treated?

A three-week-old girl was brought to the emergency
room because of intermittent twitching of her left
limbs for 4 days. The girl had been born normally
at 39 weeks of gestation and was being breast-fed.
Examination was unremarkable. Her biochemical
investigations were:

Question #2

Na+ : 125mmol/l (135-145 mmol/l)		
Cl- : 100mmol/l (101-111 mmol/l)		
K+ : 2.8mmol/l (3.6-5.0 mmol/l)
HCO3 : 30mmol/l (23-28 mmol/l)

A 60-year-old female came to ER due to fracture
neck of femur after a minor fall. Her past
complaints were of generalised body aches and
bone pains with difficulty in rising from sitting
position since two year. She was a known case
of hypertension for the past 20 years and taking
antihypertensive since then. She was diagnosed
to be osteoporotic and was considered for
bisphosphonate therapy.

Ca+ : 4.5mg/dl (8.4-10.2mg/dl)		
Albumin : 2g/dl (3.2-5.5g/dl)
PO4 : 10mg/dl (2.5-4.6 mg/dl)
PTH : <4pg/l (16-87pg/ml)

2.1: What is the most likely cause of body aches
in the patient?

1.1: What is the diagnosis?

2.2: What biochemical test can be performed to
confirm diagnosis?

1.2: Which other bone mineral is required for 		
optimal parathyroid function?

2.3: How will you monitor the response to 		
bisphosphonate therapy?

8
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Renal Osteodystrophy: A Disturbed Metabolic
Aspect of Renal Failure
Dr Sahar Iqbal
Chemical Pathology

Renal osteodystrophy is a common complication
of chronic kidney disease (CKD). It is part of a
broad spectrum of disorders of mineral and bone
metabolism that develop in this clinical setting
and result in both skeletal and extra skeletal
consequences. The term CKD-Mineral and
Bone Disorder (CKD-MBD) has been recommended
to be used to describe a broader clinical
syndrome that develops as a systemic disorder of
mineral and bone metabolism in CKD. The
manifestations include abnormalities of calcium,
phosphorous, parathyroid hormone (PTH) or
vitamin D metabolism; abnormalities in bone
turnover, mineralisation, volume, linear growth
or strength; and vascular or other soft tissue
calcification.
The term renal osteodystrophy should be used
exclusively to define alterations in the bone
morphology associated with CKD. This is a
single measure of the skeletal component of
the systemic disorder of CKD-MBD that is
quantifiable by histomorphometry of bone biopsy.
The abnormalities of the bone in the setting of
CKD may manifest as high turnover bone disease
(ostietis fibrosa or secondary hyperparathyroidism),
dynamic bone disease, osteomalacia and mixed
renal osteodystrophy.
Biochemical markers for diagnosing renal
osteodystrophy are intact PTH (iPTH), vitamin D
(25OHD), blood calcium and phosphorus levels
and bone turn over markers such as alkaline
phosphatase and N-telopeptide of type I Collagen
(NTx).
The pathogenesis of osteodystrophy is complex.
The cycle starts with the renal failure and retention
of phosphate, inhibiting calcitriol (1,25 dihydroxy
vitamin D) synthesis and decrease in calcium
through a reduction in intestinal calcium absorption.
Hypocalcaemia stimulates PTH secretion causing
high turnover renal osteodystrophy.
The biochemical picture of high turnover renal
osteodystrophy usually is an increase in blood

PTH, bone alkaline phosphatase and phosphate
concentration and low calcium and 25OHD
levels.
Low turnover bone disease is commonly observed
in dialysis patients, but has been described in
some cases even before dialysis. Adynamic bone
disease is associated with the over suppression
of parathyroid gland activity due to high calcium
intake (from diet, dialysate or calcium-containing
phosphorus binders) and/or administration of
vitamin D analogs in excess.
Patients with adynamic bone disease have lower
blood concentrations of iPTH that may fall
below the recommended target range of 150300 pg/ml of iPTH, resulting in a bone turnover
rate that is below normal. In these circumstances,
the bone may not take up calcium for incorporation
into new bone and any excess calcium may
predispose to calcification in soft tissues.
Currently in the United States, approximately
25 per cent of patients undergoing dialysis have
a iPTH concentration above the target range
(high-turnover disease), approximately 25
per cent have a PTH concentration within the
target range and 50 per cent have a PTH
concentration below the target range (adynamic
bone disease).
The ultimate goal of drug therapy in the
management of CKD is to prevent complications
of CKD, specifically bone disease and extra
skeletal calcification. Need for the evaluation,
treatment and monitoring of bone metabolism is
to prevent secondary hyperparathyroidism. At
stage 3 CKD, serum calcium, phosphorus and
iPTH concentrations should be evaluated. After
initial assessment, routine monitoring should be
performed (see table 1). Appropriate management
requires a balanced diet, phosphorus binders and
active vitamin D analogs. The recommended
ranges for corrected calcium, phosphorus and
iPTH for different stages of CKD for kidney
diseases outcomes quality initiative are shown in
Table 2.
9
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Stage of CKD
		

Measurement of iPTH
phosphorus

Measurement of calcium and

3 (30-59 ml/min/1.73 m2

Every 12 months

Every 12 months

4 (15-29 ml/min/1.73 m2

Every 3 months

Every 3 months

5 (<15ml/min/1.73 m2

Every 3 months

Every month

Table 1. Monitoring of frequency of calcium, phosphorus and intact PTH in different stages of CKD kidney diseases
National kidney foundation. Clinical practice guidelines for bone metabolism and disease. Am J Kidney Dis 2003; 42(4 supp 3): S12

Stage of CKD

Phosphorus
(mg/dl)

Corrected calcium
(mg/dl)

Serum PTH
(pg/ml)

3 (30-59 ml/min/1.73 m2

2.7-4.6

Normal range

35-70

4 (15-29 ml/min/1.73 m2

2.7-4.6

Normal range

70-110

5 (<15ml/min/1.73 m2

3.5-5.5

8.9-9.5

150-300

Table 2. Recommended ranges for phosphorus, corrected calcium and PTH for different stages of CKD.
National kidney foundation. Clinical practice guidelines for bone metabolism and disease. Am J Kidney Dis 2003; 42(4 supp 3): S12

Osteopenia and Osteoporosis in Beta
Thalassemia Major
Dr Huma Mansoori and Dr Shabina Sikandar
Haematology

Beta thalassemia major (TM) is an inherited autosomal
recessive disorder in which synthesis of beta globin
chains is compromised due to mutation of beta globin
gene culminating in ineffective erythropoiesis.
The anaemia manifests at 6 to 9 months after
birth as haemoglobin switches from HbF to HbA
with features like failure to thrive, poor feeding,
recurrent infections, pallor and enlarged spleen. In
untransfused patients haemoglobin level ranges from
3 to 6 gm/dl. However, regular blood transfusion and
compliance with prompt iron chelation therapy has
markedly improved life expectancy of thalassemics,
but morbidity due to its chronic complications like
osteopenia and osteoporosis remains there.
Osteopenia refers to bone mineral density (BMD)
that is lower than normal peak BMD but not low
10

enough to be classified as osteoporosis while
osteoporosis is characterised by low bone mass
and disruption of bone architecture, resulting in
decreased bone strength with an increased risk
of fracture.
The frequency of osteopenia or osteoporosis in
well-treated patients of TM is approximately
40-50 per cent which clearly depicts that despite
the normalisation of haemoglobin levels, adequate
hormone replacement and effective iron chelation;
thalassemics continue to show an unbalanced bone
turnover and an increased resorption resulting
in seriously diminished BMD. Bone disease in
thalassemia is manifested by diffuse bone pain,
spinal deformities like scoliosis, nerve compression
and various degrees of osteopenia, osteoporosis
and spontaneous fractures.
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Factors contributing to osteoporosis and osteopenia
in thalassemics include iron overload resulting in
endocrinopathies; which directly or indirectly leads
to decreased bone mass. There is marrow expansion
due to increased erythropoiesis causing mechanical
interruption of bone formation leading to cortical
thinning of bones. In addition, osteoblasts are also
affected by direct iron toxicity as well as due to liver
disease. Chelation therapy with desferrioxamine
inhibits DNA synthesis, osteoblast and fibroblast
proliferation, osteoblast precursor’s differentiation
and collagen formation, whereas in high doses it
enhances osteoblast apoptosis.
The serum biochemistry is usually unhelpful in
diagnosis of osteoporosis because the levels of
calcium, phosphate and PTH are generally normal.
However, markers of bone turnover such as serum
alkaline phosphatase, serum osteocalcin, and N
telopeptide of Type I Collagen (NTx) may be raised
in osteoporosis in TM. Dual energy x-ray absorption
(DXA scan) is also commonly used to assess bone
mineral density but it should be kept in mind that it
may fail to provide accurate and precise information
on osteoporosis in thalassemics as they have spinal
degenerative skeletal changes, which can be detected
only by MRI and is likely to interfere with BMD
values, resulting in false diagnosis of bone disease.
Vitamin D deficiency can also co-exist.

Following therapeutic strategies should be undertaken
to prevent and treat osteopenia/osteoporosis in TM.
l

lifestyle measures should be encouraged such as
physical activity and smoking quitting.

l

calcium and vitamin D intake during skeletal
development increases bone mass in adult life with
the final goal to prevent bone loss and fractures.

l

induction of puberty at a proper age and
treatment of hypogonadism with hormone
replacement therapy shows quite promising results
to prevent osteoporosis and other bone deformities.

l

calcitonin, a potent inhibitor of osteoclasts, in
combination with calcium and vitamin D has
shown to decrease bone pain and radiological
signs of osteoporosis.

l

alendronate, pamidronate, and zoledronic
acid have shown efficacy in osteoporotic patients
with TM either with normal or impaired gonadal
function but further research in the therapeutic
trials with bisphosphonates is needed to allow
definite conclusions especially in our setting
where vitamin D deficiency is widely prevalent.
However, they may be used as a second line
treatment if the above strategies have failed.

Role of β2 Microglobulin in Multiple Myeloma
Dr Mehreen Imran
Haematology

Multiple myeloma is a B cell malignancy characterised
by monoclonal accumulation of abnormal plasma
cells in the bone marrow (Fig. 1). The clinical signs

and symptoms of myeloma are heterogeneous and
include bone complications, symptoms of impaired
formation of blood cells and hyperviscosity, renal
dysfunction, infections, peripheral neuropathy and
extra medullary disease.
Multiple myeloma constitutes about 15 per cent of the
haematological malignancy. The disease develops in
one to four per 100,000 people per year. It is more
common in men, and is twice as common in blacks as it
is in whites. With conventional treatment, the prognosis
is three to four years, which may be extended to five
to seven years or longer with advanced treatments.

Fig. 1. Bone marrow aspirate demonstrating plasma cells of multiple myeloma

Diagnostic work up for myeloma is shown in Table 1.
One of the laboratory parameter is β2 microglobulin
11
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Laboratory Tests
Full blood count, peripheral film and ESR
Evaluation of kidney function, serum calcium, CRP,
β2 microglobulin, LDH, uric acid levels and liver
function tests
Protein electrophoresis and paraprotein quantification
Quantitative analysis of normal immunoglobulins,
24-hours urine collection for light chain (Bence Jones
protein) excretion, coagulation screen
Bone marrow aspiration and trephine biopsy for
morphology, immunophenotyping (CD138, CD79a,
kappa, lambda, CD20) and cytogenetic

multiple myeloma patients. Increased production or
destruction of plasma cells causes β2 microglobulin
level in the blood to increase. Pre-treatment values
of β2 microglobulin are thus useful in confirming
tumor mass grade, and in assessing response
to chemotherapy; marked reductions following
chemotherapy correlated well with the onset of
remission. The serum β2 microglobulin level is
one of the prognostic factors incorporated into the
International staging system. Patients with high
values have inferior survival.
The following levels of β2 microglobulin correlate
with stages of multiple myeloma:
Stage I multiple myeloma
β2 microglobulin level is lower than 3.5 mg/mL
albumin level is 3.5 g/dL or higher

Radiological Tests

l
l

Complete skeletal survey

Stage II multiple myeloma

Computerised tomography (CT)

l

Magnetic resonance imaging (MRI)
l
Table 1. Laboratory and radiological work ups for multiple mayeloma
available at AKUH

β2 microglobulin level is lower than 3.5 mg/mL
and the albumin level is lower than
3.5 g/dl
β2 microglobulin level is between 3.5 and 5.5
mg/mL

Stage III multiple myeloma
(also known as β2M) is a component of MHC
class I molecules, which are present on all white
blood cells (including plasma cells). In humans,
the β2 microglobulin protein is encoded by the β2
microglobulin gene
(Fig. 2). Normal
urinary excretion of β2
microglobulin is less
than 370 micrograms
per 24 hours. Elevated
serum concentration in
the presence of normal
glomerular filtration
rate suggests increased
microglobulin
β2
production or release,
which is seen in
lymphoproliferative
diseases such as
multiple myeloma.

Fig. 2. Structure of MHC class I β2

The increase is seen
in cancers involving
white blood cells,
but it is more meaningful in newly diagnosed

microglobulin
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l

β2 microglobulin is 5.5 mg/mL or higher.

The prognostic value of serum β2 microglobulin
level in myeloma is probably due to correlation
of levels with tumour burden. High levels are also
associated with renal failure, which carries an
unfavourable prognosis in multiple myeloma. The
reference ranges are shown in table 2.
			
Group

Median

ng/mL
2.5%ile

95%ile

97.5%ile

Males

1,556

604

2,157

2,284

424

Females 1,473

607

2,295

2,454

370

N

Table 2. Reference ranges for β2 microglobulin as reported in AKU-Laboratory

β2 microglobulin test is performed by a chemilumniscent
assay in Clinical Laboratory AKUH. It is done on
clotted blood sample of the patient; however, it can
also be performed on patient’s urine. Urine may be
a single collection or collected throughout a 24 hour
time period. The urine should be refrigerated until it is
brought to the laboratory and must not become acidic.
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Update on Microbiological Diagnosis of Bone
and Joint Disorders
Dr Kauser Jabeen
Microbiology

Prosthetic joint infections; How to effectively use the available
diagnostic modalities?
Prosthetic joint infections (PI) are associated with
substantial morbidity and costs; therefore early and
accurate diagnosis is crucial. The clinical presentation
may be non-specific and vary between different patient
populations. Effective use of the currently available
diagnostic modalities for PI results in improves
outcomes. PI occurring within three months of joint
replacement are categorized as early and 3-12 months
after surgery as delayed and >12 months as late.
A widely accepted case definition for PI includes:
l
purulence around a prosthesis at arthrotomy or
arthroscopy
l
presence of one or more sinus tract 			
communicating with the joint
l
histological features of infection
l
isolation of similar organism from at least two
deep culture samples. Isolation of virulent 		
organisms, such as Staphylococcus aureus, 		
Escherichia coli, or Candida spp., in one deep
tissue sample may be considered as significant
to confirm the diagnosis.
Gram positive organisms, especially Staphylococci
(commensal skin organisms), are most commonly
involved and in early infection, pathogens are usually
more virulent (for example, Staphylococcus aureus),
Gram positive organisms

whereas more indolent organisms predominate later
on (for example, coagulase negative staphylococci,
Propionibacterium acnes) (Table 1).
Laboratory investigations
Detection of inflammatory markers:
Baseline blood tests for inflammatory markers including
C reactive protein (CRP), erythrocyte sedimentation
rate (ESR), leukocyte count should be performed
for any suspected case. These parameters may be
elevated up to two weeks after surgery and cannot be
relied upon in early infection. Serial measurements
of these markers are recommended and persistently
or progressively high inflammatory markers most
likely reflect infection. It is important to note however,
that a normal result does not exclude joint infection
especially if the pathogen is of low virulence.

Cultures:
Blood for culture should be taken in every case
before starting antibiotics as even a single dose is
known to decrease the diagnostic yield. In most
cases however, it is difficult to take deep cultures
before starting antibiotics in patients with systemic
sepsis or rapidly evolving
Gram negative organisms
Fastidious organisms local infection.
Superficial swabs should
not be collected as they most
Mycobacteria
likely reflect colonising
flora and results must
therefore be interpreted
Fungi
with caution. Deep samples
of synovial fluid and tissue
taken during arthrotomy/
arthroscopy, or by joint
aspiration are needed
for definitive diagnosis.
Organisms should be identified accurately as treatment

Coagulase negative staphylococci Enteric Gram negative bacilli Anaerobes
Methicillin sensitive
Pseudomonas spp
Staphylococcus aureus
		
Methicillin resistant S aureus 		
Streptococcus spp 		
Enterococcus spp 		
Diphtheroids (Corynebacterium
spp, Propionibacterium spp)
Table 1. Organisms commonly involved in prosthetic joint infections
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options differ for different organisms (Fig.1 and Fig. 2).
Identification of similar organisms from at least three
culture samples is highly predictive of infection and

Fig. 2. Photomicrograph on the left showing Gram stain of Propionibacterium species; this organisms requires anaerobic conditions

Fig. 1. Coagulase test that is required to differentiate between Staphylococcus
aureus and other Staphylococcus species; two most common organisms responsible for prosthetic joint infections. Upper tube is coagulase positive confirming
the identity of this organisms as Staphylococcus aureus

to increase sensitivity and specificity multiple (five
to six) samples should be sent for culture. Organisms
associated with prosthetic-joint infection usually form
biofilms thus culture of prosthesis by vortexing and
sonication than conventional peri-prosthetic tissue
culture is more sensitive and specific especially in
patients with prior antibiotic treatment. Cultures
should also be hold for longer duration if fungi or
mycobacteria are suspected as causative organisms.

Other diagnostic modalities:
Apart from culture histopathology is an essential
adjunct to microbiology in the diagnosis of infection.
An elevated white cell count and neutrophil differential
of the synovial fluid are also suggestive of infection.
Serial plain radiographs may help in detecting
loosening or bone loss in chronic PI. Ultrasound
should be performed to confirm effusion and to
facilitate aseptic aspiration. Computed tomography
and magnetic resonance imaging may be useful in
the evaluation of complex cases, but metal inserts
interfere with these tests, and abnormalities may be
non-specific.

Bone and joint infections: Laboratory Diagnosis
Bone and joint infections occur as a result of
haematogenous seeding, contiguous spread of
infection to bone from adjacent soft tissues, or direct
inoculation of infection as a result of trauma or surgery.
Haematogenous spread is more common in children
while contiguous spread is commoner in adults.
Contiguous infection may be either polymicrobial
or monomicrobial while haematogenous infection
is usually monomicrobial. Staphylococcus aureus,
coagulase-negative staphylococci, and aerobic gramnegative bacilli are the most common organisms; less
common pathogens include streptococci, enterococci,
fastidious gram negative organisms and anaerobes.
Mycobacteria, Brucella spp. and fungi have also been
reported in appropriate endemic and clinical settings.
Diagnosis; General Considerations
Cultures: Several factors should be considered while
14

investigating for the diagnosis of these infections.
The most important factor is specimen collection as
it is extremely important to prevent contamination
by normal flora. The samples should be collected as
tissue or fluid rather than swabs because:
l
they are more likely than tissue or fluid to be
contaminated
l
the amount sent for culture is often insufficient
l
they may inhibit the growth of certain 		
pathogens
l
fastidious organisms survive less well in 		
swabs than in aspirated fluid or pus
l
bacteria may adhere to swabs and give a 		
false-negative microscopy result
Ideally, culture specimens should be taken before
antibiotics are commenced. In practice, however,
empirical antibiotics may be commenced before
culture specimens are taken.
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Bone and Joint Infections: Laboratory Diagnosis
If Mycobacteria or fungi are suspected as etiologic
agents; specimens should be sent for mycobacterial
and fungal culture in addition to culture for
routine organisms.
Histopathology: Histopathology and cytology not
only provide rapid results than culture but also
guide in assessing the significance of cultures.
However the tissue Gram stain is an insensitive
test for detecting bacteria as fixing and processing
including chemical decalcification, adversely
affects the Gram stain characteristics.
Nucleic acid amplification tests: There is little
published information regarding the role of nucleic
acid amplification based methods for skin, bone, joint,
and soft-tissue infections. Therefore, routine use of
nucleic acid amplification is not recommended for the
diagnosis of these infections. Although these techniques
may prove useful in selected cases where fastidious
organisms are suspected as cause of infection.
Bone Infections
Close communication between clinician, radiologist
and pathologist/microbiologist is required for optimum
diagnosis. Excisional bone biopsy is required in cases
in which clinical and radiographic features are not
diagnostic. In all cases however, culture is essential
for identification and antimicrobial susceptibility
testing. For that an adequate amount of tissue should
be sent to the microbiology laboratory. For chronic
osteomyelitis, culture of an infected bone specimen
is necessary to establish the diagnosis. Blood culture
should also be sent to aid the diagnosis if the patient is
septic. A positive culture precludes the need for more
invasive procedures if the organism isolated from
blood is a likely pathogen to cause osteomyelitis.

Serial measurements of serum C-reactive protein
levels and erythrocyte sedimentation rates are also
commonly used to monitor response to therapy. The
CRP is a more sensitive parameter than the ESR.
Joint Infections
Synovial fluid analysis is useful in establishing
diagnosis and presence of pus suggest the possibility
of infection (Fig. 2). Joint fluid should be cultured
for both aerobic and anaerobic bacteria. Blood

Fig. 2. Pus sample aspirated from infected knee joint highly suggestive of
infection. Photomicrograph on the right is showing Gram stain of same
sample revealing numerous pus cells and Gram positive cocci in clusters

culture bottles should not be used to culture joint
fluid as they have not been evaluated for yield for
culturing joint fluid (Fig. 3). Fluid aspirated from
joints should be collected aseptically, transferred
to a sterile container (or left in the syringe), and

Cultures of superficial wounds and sinus tracts are
of no value because the results do not correlate
reliably with the pathogen in the underlying bone
except if Staphylococcus aureus or Salmonella spp
are isolated (Fig. 1).
Fig. 3. Blood culture bottles should not be used to culture joint fluid;
fluid aspirated should be transferred to a sterile container

Fig. 1. Swabs from superficial wounds and sinus tract should not be sent
as the organisms isolated do not correlate with the pathogen in bone

sent immediately to the laboratory. Cultures for
Neisseria gonorrhoeae should be transported
immediately to the laboratory. Specimens to be
submitted for mycobacterial culture do not require
special handling.
15
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Mycetoma: Microbiological Diagnosis
Mycetoma is a chronic inflammation of skin
and subcutaneous tissue caused by either
fungi (eumycetoma) or filamentous bacteria
(actinomycetoma). This infection most commonly
presents as a progressive, subcutaneous swelling with
development of multiple nodules. These nodules later
develop into sinuses with discharging grains (Fig. 1).

Fig. 2. Discharging grain from a case of mycetoma

cultures as the specimens may become contaminated
with bacteria or fungi from skin or sinus tracts. The
superficial material from sinus tracts should never be
sent for culture as it will likely grow mixed flora that
does not represent the actual cause of infection.
Fig. 1. Mycetoma of the foot

As the disease progresses involvement of bones and
in advanced cases osteoporosis and bone destruction
can occur. The organisms responsible for mycetoma
are present in the soil and enter the subcutaneous
tissue by traumatic inoculation. This infection is
mainly seen in tropical regions and Pakistan is one
of the endemic countries. Mycetoma commonly
affects adults aged 20 to 40 years, predominantly
males. The foot is the most commonly affected site
(80 per cent of the cases).
Diagnosis
Diagnosis is usually determined clinically; however
radiology is required to assess the extent of
spread and involvement of bone and joints. Visual
examination of colour of discharging grains is crucial
for identification of possible etiologic agent (Fig. 2).
In addition to that microscopic examination after
crushing the grains between two slides should be
performed to visualise fungal or bacterial elements
(Table 1). Specimen should also be cultured
for fungi and aerobic actinomycetes (Fig. 3). If
granules are not present, an excisional biopsy for
culture and histopathology or cytology is essential.
Histopathology is also important for correlation with
16

Fig. 3. Culture plate and photomicrograph showing Madurella spp.;
commonest agent of eumycetoma
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Etiologic agents

Colour of the grains

Eumycetoma species
Madurella mycetomatis

Black

Madurella grisea

Black

Fusarium spp

White

Acremonium spp

White

Actinomycetoma species
Nocardia brasiliensis

White

Nocardia asteroides

White

Streptomyces somaliensis

White

Actinomadura madurae

White

Actinomadura pelletieri

Red

Table 1. Common etiologic agents of mycetoma

Bone Sarcomas: Role of Histopathology in
Diagnosis
Dr Fatima A Firdousi
Histopathology

Primary bone tumors are rare with relatively high
incidence in children and adolescents. They are
difficult to recognise as malignant by clinicians,
radiologists, pathologists and leads to major
diagnostic difficulties.
Table 1 shows 2002 WHO classification of malignant
bone tumour. Osteosarcoma usually arises in the
metaphysis of long bones, most commonly around
the knee. Risk factors for osteosarcoma include
previous radiation, Paget’s disease of bone and germ
line abnormalities (Fig. 1). Ewing sarcoma (ES) is
the second most common bone cancer. About 25
per cent of the patients have ES of the pelvic bones,
while 50 per cent have extremity tumours (Fig. 2).
Chondrosarcoma is most frequently encountered
in adults arising in the diametaphyseal region of
long bones. Most of them are low grade (Fig. 3).

Fig. 1. Conventional osteosarcoma

Enchondroma and
osteochondroma
can also give rise to
chondrosarcoma;
most are solitary
but can occur as
multiple lesions.
Other sarcomas
like spindle cell
sarcomas of bone,
malignant fibrous
histiocytoma/
fibrosarcoma,
lieomyosarcoma,
undifferentiated
sarcoma,
all
present with pain
and fracture.
17
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Osteogenic tumours

Osteosarcoma,
Conventional,
(chondroblastic, fibroblastic, osteoblastic)
Telangiectatic,
Small cell,
Low-grade central,
Secondary,
Parosteal,
Periosteal,
High-grade surface

Ewing Sarcoma/ PNET

Ewing sarcoma

Cartilage

Chondrosarcoma,
Central, primary and secondary,
Peripheral,
Dedifferentiated,
Mesenchymal,
Clear cell

Fibrogenic Tumours

Fibrosarcoma

Fibrohistiocytic Tumours

Malignant fibrous histiocytoma

Haematopoietic Tumours

Plasma cell myeloma,
Malignant lymphoma, NOS

Giant Cell Tumour

Malignancy in giant cell tumour

Notochordal Tumour

Chordoma

Vascular Tumours

Angiosarcoma

Smooth Muscle Tumours

Lieomyosarcoma

Lipogenic Tumours

Liposarcoma

Miscellaneous Tumours

Adamantinoma

Table 1. Classification of bone sarcoma
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The pathologist should be directly consulted by
frozen section after taking the biopsy in case more
material is required. In bone sarcomas, to prevent
local recurrence biopsy tract should be removed
with the resection specimen. Biopsy tracts should be
tattooed by ink.
Material should ideally be transported to the lab within
half an hour, touch preps can be taken before formalin
fixation of the biopsy material. All patients should
have a bone marrow biopsy and aspirate performed
before starting treatment.
Fig. 1. B Osteoblastic osteosarcoma

The likely diagnosis of a bone tumor is related
to age. Metastatic neuroblastoma or eosinophilic
granuloma is seen in children below 5 years while
primary bone sarcomas are found in children above
5 years of age. In adult’s greater then 40 years, it is
usually metastaic or myeloma.
Radiographs in 2 planes are the first investigation
to confirm the diagnosis and to localise the
tumour so that biopsy can be performed. CT
should be used in a case of diagnostic problem
or doubt. MRI of the whole bone with adjacent
joints is the next step for local staging.

Fig. 3. Chondro sarcoma grade II

The biopsy request should carry information regarding
the origin of tumour, preoperative findings and any
chemotherapy received. Related information should
also be provided with the biopsy material to the
laboratory like nature of the bone specimen, segmental
recession, curettage, needle biopsy, limb amputation
or any other complex recession.

Fig. 2. Ewing sarcoma

Biopsy should be taken to prevent minimal
contamination of normal tissue with the
tumor cells. Samples should be taken for
microbiological culture and histology. Core
needle biopsy is preferred and with aid of staging
studies the primary location of biopsy can be
chosen. Excision biopsy is contraindicated for
all cases with a possibility of aggressive and
benign lesion.

The bone tumour biopsies are decalcified in
Histopathology Section at AKUH, The size of the
tumour measured in 3 dimensions (in mm) with
histological features and tumour type. Tumour
necrosis whether less than or more than 90 per cent is
included. The resection margins whether involved or
clear by the tumour is also measured in mm.
Routine H&E staining is performed of the biopsy
material. In ES special stain like PAS+ and
immunostain CD99 (MIC 2) is also performed.
The results of immunohistochemical stains using
SNOMED or ICD-0 codes are recorded.
Reference:
Annals of Oncology 21 (Supplement 5):
v204-v213, 2010
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HLA B-27 at a Glance
Sheeba Parveen
Molecular Pathology

HLA (Human leukocyte antigen) B-27 is
class I surface antigen which is encoded by
genes present on short arm of chromosome 6

such as viruses and bacteria ‘non-self’. HLA B-27
is strongly associated with the condition ankylosing
spondylitis, which is named due to the terms
‘Ankylosing’ or fusing together and ‘spondylitis’
or inflammation of bones of spine. This and
other associated inflammatory diseases are
collectively referred to as ‘spondyloarthritis’. It is
uncertain how HLA B-27 causes increase risk of
ankylosing spondylitis.
Researchers speculates that HLA B-27 may
abnormally display to immune system peptides that
trigger arthritis other researchers suggests that joint
inflammation characteristic of this disorder may
result from improper folding of HLA B-27 protein
or the presence of abnormal forms of the protein on
the cell surface.
Ankylosing spondylitis is two to three times more
common in males than in females, and it affects all
age groups including children. The most common
age of onset of symptoms is the second and third
decade of life. The effect of the disease is depicted
in Fig. 1B Symptoms of ankylosing spondylitis
include back pain and stiffness (worst at night and

Fig.1.A. The organization of HLA genes on chromosome 6

(Fig. 1A). The HLA genes are the human versions
of MHC genes that are found in most vertebrates.
The proteins encoded by certain genes are also
known as antigens, as a result of their historic
discovery as a factor in organ transplantation.
The major HLA antigens are essential elements
for immune function. Different classes have
different functions.
The role of HLA B-27 molecules is presentation
of peptides to T-cells. The immune system uses
HLAs to distinguish the body its own proteins
‘self’ from the proteins made by foreign invaders
20

Fig.1.B. Diagrammatic representation of the effect of ankylosing spondylitis on the spine.

in morning), weight loss, feeling unwell, tiredness,
pain and swelling of hips, knee or joints, plantar
fasciitis (pain under heel of foot), aching in chest,
around ribs. It may be associated with psoriatic,
colitic and reactive arthiritis. The complications of
the disease are uveitis (inflammation of eye) and
issues related to heart and lungs.
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For molecular diagnosis of ankylosing spondylitis
a venous blood sample is required for the test.
DNA is extracted from blood using the sodium
dodecyl sulphate (SDS)-proteinase K lyses method
and then amplified by conventional polymerase
chain reaction (PCR). Using Sequence specific
primer (HLA-A and HLA–B) primers. In addition,
PCR for the growth hormones (GH 1 and GH 2) genes
is used as an internal control. Amplified product is
than analysed by agarose gel electrophoresis (Fig.
2).
A positive band of 144 kb obtained in the PCR
reaction indicates the presence of the HLA-B27
allele, and based on this the result of the test is
reported as a ‘presence’ or an ‘absence’ of the
HLA B27 allele. An internal control is included in
each PCR reaction to monitor the presence of PCR
inhibitors in the specimen.

Fig. 2. Detection of the HLA B-27 all ele. The picture depicts the presence of DNA on an agarose gel stained with ethi dium bromide. Fluorescent bands indicate the presence of DNA in each lane

Meeting Reports
Seema Vaqar
Clinical Labortory

Multiple CME seminars were held at different cities in
Pakistan as a part of continuing educational activities
of the Department of Pathology and Microbiology,
where faculty presented the latest advancements
and updates in medical and laboratory sciences.
CME Seminar held at Hotel City Centre Baldia
Complex, Mirpurkhas on February 09, 2011,
covered broad range of topics on chronic hepatitis
B and hepatitis C interpretation, diagnosis and
management, vitamin D deficiency and approach
to diagnosis of anaemia. It was well attended by
general practitioners, physicians, surgeons,
of
District
Civil
Hospital,
Muhammad
Medical college Hospital Mirpurkhas and
nearby periphery towns i.e. Digri, Umer Kot, and
Tando Allahyar.
Dr Yasmeen Khoonharo, Assistant Professor
and Consultant Gynaecologist and Obstetrician,
Muhammad
Medical
College
Mirpurkhas
appreciated role of AKUH pathologists in educating
as well as providing high quality diagnostic
services for physicians and hospitals nationwide.
Dr Mahadev Harani referred to data obtained by

the AKUH Clinical Laboratories for differential
diagnosis of anaemia with histogram. He
emphasised diagnosis and management of anaemia
by detail history and laboratory investigations.
Dr Aysha Habib Khan Consultant Chemical
pathologist, highlighted the wide spread
prevalence of vitamin D deficiency in Pakistan,
She presented data from healthy volunteers and

Presenters and organisers of the CME at Mirpur Khas
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CME held on February, 9 2011 at Fatima Memorial
Hospital College of Medicine and Dentistry Lahore,
was well attended by health care professionals
and consultants from all disciplines of Hospital.

Dr Farooq Ghani addressing the audience at CME

ambulatory care patients highlighting the need
to diagnose and treat these case at an early stage.
She shared that testing in form of bone health
profile is available at AKUH Clinical Lab; the
profile is developed to answer the potential
clinical questions that a physician has, if a patient
is suspected of having a metabolic bone diseases.
Dr Syed Zafar Abbas Consultant Physician and
Gastroenterologist,
Medical
Superintendent
Muhammad Medical Hospital Mirpurkhas and
Dr Romena Qazi Assistant Professor and
Section head Molecular Pathology AKU both
address the chronic issue of hepatitis B and C
prevalence and management of the infection,

Dr Farooq Ghani, Associate Professor and Director
out reach laboratory services addressed about
‘Diagnostic Approach to Genetic Disorders’ and
Triple Marker Screening test. He introduced
advancement in technology and importance of
maternal blood screening test for Down’s syndrome
and neural tube defects in his presentation. Dr
Sara Malik explained about ‘Serum Markers in
Prenatal Diagnosis’, where the fetus is treated as
patient. She shared that approximately three per
cent of all pregnancies have a genetic disorder or
birth defect. Dr Ayesha Ehsan in her presentation
explained about maternal blood sampling
for testing for fetal DNA in maternal blood.
CME seminar was held at Thalassaemia Care
Center, Badin with on 22nd February 2011.
Dr Muhammad Haroon, Pathologist at Civil

Speakers at CME Seminar on Recent Advances in Pediatrics Pathology

hospital and In-charge Thalassaemia Care Center
at Badin presided over the session.

Dr Sara Malik receiving her shield from Prof. Sabiha Riyaz

diagnosis of Hepatitis C by PCR was emphasised
and stressed by the speakers as an important step in
management.
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Dr Bushra Moiz, Associate Professor and Consultant
Haematologist, AKUH delivered an interactive
talk on ‘How to investigate a bleeding patient?’
She emphasised on taking a detailed history of a
bleeding patient along with physical examination
and recommended complete blood count with
peripheral film review for correct platelet estimation,
bleeding time (BT), prothrombin time (PT),
activated partial thromboplastin time (APTT) and
urea-clot lysis test as first line tests. The
last is required to detect factor XIII deficiency
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which cannot be tested by PT and APTT alone. She
emphasised the review of platelet film in case of low
platelets as spurious results are sometimes generated
by analysers in the presence of platelet clumps and
large or giant platelets. The screening tests assist in
making a presumptive diagnosis in conjunction with
clinical details. Based on these tests, the doctor
should order more specific tests e.g if von Willebrand
disease is suspected than vWAg, RiCof and factor
VIII assay are required for proper evaluation. She
also stressed that all such patients should be referred
to haematologists for proper assessment. Ordering
of all tests is neither required nor financially viable
hence an appropriate understanding of underlying
pathology is utmost essential for correct diagnosis
and management of the bleeding disorder. AKUH
laboratory offers all routine and specialized
tests required for diagnosis of various
bleeding disorders.
The talk was followed by a question-and-answer
session where doctors showed their keen interest in
management of bleeding disorders.

CME Seminar on ‘Recent Advances in
Pediatrics Pathology’ was held at auditorium
of
King
Edward
Medical
University/
Mayo Hospital Lahore on March 8th 2011
Professor Mahmood Shaoukat shared his vision
about the ‘Use of Stem Cells in Trauma and Burn
Management. Prof Farah Asghar explained about
‘Fetal anomalies screening’. She stated that
congenital abnormalities account for 20-25 per
cent of prenatal deaths. Dr Farooq Ghani spoke
about the ‘Prenatal Diagnosis of Birth Defects’
and explained the techniques and methods
of prenatal testing. He talked about common
chromosomal and genetic disorders seen in our
population and shared his experience of prenatal
testing at AKU.
Dr Shahid Pervaiz, Professor Department of
Pathology and Microbiology presented about the
common childhood leukemias and lymphomas seen
in our population and how the accurate diagnosis
can impact patient management.

Answer to LABRAD Quiz
1.1:

Hypoparathyroidism is the most common
cause of hypocalcemia, which is causing
symptoms in this patient. Her presentation
soon after birth suggests presence of
congenital hypoparathyroidism.

1.2:

Serum magnesium levels: Magnesium is
required for optimal activity of parathyroid
gland. Levels are usually low in
hypoparathyroidism.

1.3:

The goal of treatment is to normalise the
levels of calcium, magnesium and
phosphorus. A treatment regimen typically
includes replacing calcium by giving
oral calcium carbonate or gluconate along
with 1 alpha vitamin D.

2.1:

Symptoms of bone pain and weakness
can mean that patient have a coexistent

vitamin D deficiency along with senile
osteoporosis. For many people, the symptoms
are subtle. Yet even without bone symptoms,
inadequate vitamin D levels can pose other
health risks
2.2:

Biochemical tests to measure calcium,
phosphorus, magnesium, vitamin D and
parathyroid hormone and bone turnover
markers can be performed. Depending
upon the symptomatology, tests to screen for
secondary osteoporosis can also be considered.

2.3:

Bone tumor markers (BTM) are helpful
in monitoring bisphosphonate therapy.
Early changes in BTM measure the clinical
efficacy of an anti-resorptive treatment
and to reinforce patient compliance. At
AKUH Clinical Laboratory, N-telopeptide of
Type I collagen is performed.
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